Cargando…

Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial

INTRODUCTION: Preterm birth accounts for more than 85% of all perinatal complications and deaths. Seventy-five per cent of early preterm births (EPTBs) occur spontaneously and without identifiable risk factors. The need for a broadly applicable, effective strategy for primary prevention is paramount...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shao J, Best, Karen, Gibson, Robert, McPhee, Andrew, Yelland, Lisa, Quinlivan, Julie, Makrides, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623491/
https://www.ncbi.nlm.nih.gov/pubmed/28947468
http://dx.doi.org/10.1136/bmjopen-2017-018360
_version_ 1783268099757178880
author Zhou, Shao J
Best, Karen
Gibson, Robert
McPhee, Andrew
Yelland, Lisa
Quinlivan, Julie
Makrides, Maria
author_facet Zhou, Shao J
Best, Karen
Gibson, Robert
McPhee, Andrew
Yelland, Lisa
Quinlivan, Julie
Makrides, Maria
author_sort Zhou, Shao J
collection PubMed
description INTRODUCTION: Preterm birth accounts for more than 85% of all perinatal complications and deaths. Seventy-five per cent of early preterm births (EPTBs) occur spontaneously and without identifiable risk factors. The need for a broadly applicable, effective strategy for primary prevention is paramount. Secondary outcomes from the docosahexaenoic acid (DHA) to Optimise Mother Infant Outcome trial showed that maternal supplementation until delivery with omega-3 (ω-3) long chain polyunsaturated fatty acid (LCPUFA), predominantly as DHA, resulted in a 50% reduction in the incidence of EPTB and an increase in the incidence of post-term induction or post-term prelabour caesarean section due to extended gestation. We aim to determine the effectiveness of supplementing the maternal diet with ω-3 LCPUFA until 34 weeks’ gestation on the incidence of EPTB. METHODS AND ANALYSIS: This is a multicentre, parallel group, randomised, blinded and controlled trial. Women less than 20 weeks’ gestation with a singleton or multiple pregnancy and able to give informed consent are eligible to participate. Women will be randomised to receive high DHA fish oil capsules or control capsules without DHA. Capsules will be taken from enrolment until 34 weeks’ gestation. The primary outcome is the incidence of EPTB, defined as delivery before 34 completed weeks’ gestation. Key secondary outcomes include length of gestation, incidence of post-term induction or prelabour caesarean section and spontaneous EPTB. The target sample size is 5540 women (2770 per group), which will provide 85% power to detect an absolute reduction in the incidence of preterm birth of 1.16% (from 2.45% to 1.29%) between the DHA and control group (two sided α=0.05). The primary analysis will be based on the intention-to-treat principle. TRIAL REGISTRATION NUMBER: Australia and New Zealand Clinical Trial Registry Number: 2613001142729; Pre-results.
format Online
Article
Text
id pubmed-5623491
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56234912017-10-10 Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial Zhou, Shao J Best, Karen Gibson, Robert McPhee, Andrew Yelland, Lisa Quinlivan, Julie Makrides, Maria BMJ Open Obstetrics and Gynaecology INTRODUCTION: Preterm birth accounts for more than 85% of all perinatal complications and deaths. Seventy-five per cent of early preterm births (EPTBs) occur spontaneously and without identifiable risk factors. The need for a broadly applicable, effective strategy for primary prevention is paramount. Secondary outcomes from the docosahexaenoic acid (DHA) to Optimise Mother Infant Outcome trial showed that maternal supplementation until delivery with omega-3 (ω-3) long chain polyunsaturated fatty acid (LCPUFA), predominantly as DHA, resulted in a 50% reduction in the incidence of EPTB and an increase in the incidence of post-term induction or post-term prelabour caesarean section due to extended gestation. We aim to determine the effectiveness of supplementing the maternal diet with ω-3 LCPUFA until 34 weeks’ gestation on the incidence of EPTB. METHODS AND ANALYSIS: This is a multicentre, parallel group, randomised, blinded and controlled trial. Women less than 20 weeks’ gestation with a singleton or multiple pregnancy and able to give informed consent are eligible to participate. Women will be randomised to receive high DHA fish oil capsules or control capsules without DHA. Capsules will be taken from enrolment until 34 weeks’ gestation. The primary outcome is the incidence of EPTB, defined as delivery before 34 completed weeks’ gestation. Key secondary outcomes include length of gestation, incidence of post-term induction or prelabour caesarean section and spontaneous EPTB. The target sample size is 5540 women (2770 per group), which will provide 85% power to detect an absolute reduction in the incidence of preterm birth of 1.16% (from 2.45% to 1.29%) between the DHA and control group (two sided α=0.05). The primary analysis will be based on the intention-to-treat principle. TRIAL REGISTRATION NUMBER: Australia and New Zealand Clinical Trial Registry Number: 2613001142729; Pre-results. BMJ Publishing Group 2017-09-24 /pmc/articles/PMC5623491/ /pubmed/28947468 http://dx.doi.org/10.1136/bmjopen-2017-018360 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Obstetrics and Gynaecology
Zhou, Shao J
Best, Karen
Gibson, Robert
McPhee, Andrew
Yelland, Lisa
Quinlivan, Julie
Makrides, Maria
Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial
title Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial
title_full Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial
title_fullStr Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial
title_full_unstemmed Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial
title_short Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial
title_sort study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 lcpufa supplementation to reduce the incidence of preterm birth: the orip trial
topic Obstetrics and Gynaecology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623491/
https://www.ncbi.nlm.nih.gov/pubmed/28947468
http://dx.doi.org/10.1136/bmjopen-2017-018360
work_keys_str_mv AT zhoushaoj studyprotocolforarandomisedcontrolledtrialevaluatingtheeffectofprenatalomega3lcpufasupplementationtoreducetheincidenceofpretermbirththeoriptrial
AT bestkaren studyprotocolforarandomisedcontrolledtrialevaluatingtheeffectofprenatalomega3lcpufasupplementationtoreducetheincidenceofpretermbirththeoriptrial
AT gibsonrobert studyprotocolforarandomisedcontrolledtrialevaluatingtheeffectofprenatalomega3lcpufasupplementationtoreducetheincidenceofpretermbirththeoriptrial
AT mcpheeandrew studyprotocolforarandomisedcontrolledtrialevaluatingtheeffectofprenatalomega3lcpufasupplementationtoreducetheincidenceofpretermbirththeoriptrial
AT yellandlisa studyprotocolforarandomisedcontrolledtrialevaluatingtheeffectofprenatalomega3lcpufasupplementationtoreducetheincidenceofpretermbirththeoriptrial
AT quinlivanjulie studyprotocolforarandomisedcontrolledtrialevaluatingtheeffectofprenatalomega3lcpufasupplementationtoreducetheincidenceofpretermbirththeoriptrial
AT makridesmaria studyprotocolforarandomisedcontrolledtrialevaluatingtheeffectofprenatalomega3lcpufasupplementationtoreducetheincidenceofpretermbirththeoriptrial